The results suggested that annual MRI screening from 30 to 35 years, followed by annual mammography at 40 years, might reduce breast cancer mortality by over 50% for women with ATM, CHEK2, and PALB2 P/LP variants [161]. This evidence concerns the gene CHEK2 and breast carcinoma.